<div class="pk-crumbs" data-crumbs="[{&quot;label&quot;:&quot;Drugs&quot;,&quot;href&quot;:&quot;README.md&quot;},{&quot;label&quot;:&quot;C02C&quot;,&quot;href&quot;:&quot;atc/C02C.md&quot;},{&quot;label&quot;:&quot;guanethidine&quot;}]"></div>

# guanethidine

- **generic name:** guanethidine
- **ATC codes:** `C02CC02`, `C02LF01`, `S01EX01`
- **DrugBank:** [DB01170](https://go.drugbank.com/drugs/DB01170) · **PubChem:** [CID 3518](https://pubchem.ncbi.nlm.nih.gov/compound/3518)
- **molar mass:** 198.3085 g/mol (C10H22N4) — DrugBank
- **groups:** approved, withdrawn

## About

Guanethidine is a peripherally acting sympatholytic antihypertensive drug that was used to treat arterial hypertension and, in eye-drop form, glaucoma. It has been withdrawn and is no longer in clinical use.

<small>Summary written by `glm-5.3-flash` from [Wikidata Q420673](https://www.wikidata.org/wiki/Q420673) and the WHO ATC classification; not checked by a person.</small>

## Extraction summary

| extracted at | time | popPK e/r/o | PD e/r/o (paper) | PGx e/r/o | tokens in/out | LLM | papers | GROBID/JATS | OA/non-OA | NONMEM |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-30 06:20 | 5:18 | 0/0/0 | 0/1/0 | 0/0/0 | 36,691/2,011 | ollama / qwen3.8:27b-mtp-q8_0 | 1 | 2/1 | 1/0 | 0 |

## popPK records

_not available_

## Pharmacodynamics (PD)

| status | detail | about | model | citation | doi |
|---|---|---|---|---|---|
| <span class="pk-badge pk-badge--red">rejected</span> | [Silva_2005_E50_relaxation](drugs/drug_guanethidine/pd_Silva_2005_E50_relaxation.md) | relaxation of precontracted human corpus cavernosum strip (percent of tonic K+ 40 mM contraction) ← phentolamine · direct Emax (saturable) effect | — | Silva LF et al., Phentolamine relaxes human corpus caver…, International journal of im… (2005) | [10.1038/sj.ijir.3901269](https://doi.org/10.1038/sj.ijir.3901269) |

## ADME sites

Where this drug is handled, from DrugBank's curated enzymes / transporters / carriers and the KB's PGx genes, mapped to tissue through the ADME gene table. Compare it with other drugs on the [Sites & interactions](sites?drugs=guanethidine) page (add drugs there; the set becomes a link).

| process | tissue | actors (role) | evidence |
|---|---|---|---|
| absorption | small intestine | <sub>named in DrugBank's ADME text</sub> | prose |
| metabolism | kidney | <sub>named in DrugBank's ADME text</sub> | prose |
| metabolism | liver | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | kidney | <sub>named in DrugBank's ADME text</sub> | prose |
| excretion | liver | <sub>named in DrugBank's ADME text</sub> | prose |

<sub>Actors without a tissue in the table: SLC6A2 (inducer).</sub>

<details class="legend">
<summary>Badge legend — what each badge means</summary>
<table><thead><tr><th>badge</th><th>what it means</th></tr></thead><tbody><tr><td><span class="pk-badge pk-badge--green">curated</span></td><td>hand-authored by a person — an exemplar, not an extraction.</td></tr><tr><td><span class="pk-badge pk-badge--green">extracted</span></td><td>the pipeline accepted the record: every closed-form check it could run passed.</td></tr><tr><td><span class="pk-badge pk-badge--green">reviewed — candidate</span></td><td>the reviewer ran the built model against the paper's own reported values and they agree — the best automatic verdict there is.</td></tr><tr><td><span class="pk-badge pk-badge--green">accepted (caveats)</span></td><td>the model replicates the paper, but an advisory check failed — the record page names the caveat under the badge and the drug page shows it under the status.</td></tr><tr><td><span class="pk-badge pk-badge--orange">needs review</span></td><td>extracted, then a check failed or a value looks implausible. The numbers are shown as read, not endorsed.</td></tr><tr><td><span class="pk-badge pk-badge--orange">built, not shipped</span></td><td>a model was built, but a core parameter fell back to a library default, so it is not shipped.</td></tr><tr><td><span class="pk-badge pk-badge--red">rejected</span></td><td>not accepted — the record is not a compartmental model, or nothing usable was extracted.</td></tr><tr><td><span class="pk-badge pk-badge--neutral">not modelled</span></td><td>pipeline state, not a judgement: no model has been built for this record yet (likewise `not simulated`).</td></tr><tr><td><span class="pk-badge pk-badge--stale">stale</span></td><td>the reviewer's verdict predates the latest re-run of the paper — treat the status as out of date, not as current.</td></tr><tr><td><span class="pk-badge pk-badge--green">cross-checked ✓</span></td><td>every independent reader agreed on every compared field. With more than one reader the badge counts them, e.g. 'cross-checked ✓ 2/2'.</td></tr><tr><td><span class="pk-badge pk-badge--orange">cross-check: partial</span></td><td>a reader differs on a non-structural field (a population label, a flag), or the readers do not all agree with each other.</td></tr><tr><td><span class="pk-badge pk-badge--red">cross-check: disputed</span></td><td>at least one reader differs on a structural parameter — a clearance, a volume, ka, a lag. The record still holds the FIRST reading; the disagreement is a signal for a reviewer, never an automatic correction.</td></tr><tr><td><span class="pk-badge pk-badge--species">rat</span></td><td>the data come from an animal (or in-vitro) study, not from people. The record, its model and its simulation are kept — they describe that species.</td></tr></tbody></table>
<p><small>The first badge is the record's <b>status</b> — what the pipeline and the reviewer concluded. A second badge, when present, is the <b>cross-check</b>: whether a model of another family, re-reading the same paper, extracted the same numbers. They are independent — a rejected record can be cross-checked, and a confirmed reading can still fail a plausibility check.</small></p>
</details>

## Coverage

- **PubMed hits:** 155 matched, 88 returned
- **screened:** 2  ·  **relevant:** 0
- **records:** 0  ·  extracted 0  ·  needs_review 0  ·  rejected 0  ·  stale 0
- **scholar-agent fallback query used:** True

## Full text wanted

_12 paper(s) judged relevant from the abstract, with no full text on disk — paywalled, or the resolver could not reach them. Follow the DOI, then save the PDF into `papers/` as `&lt;save as&gt;.pdf` and re-run the extraction._

| save as | citation | domain | score | DOI | PubMed | why wanted |
|---|---|---|---|---|---|---|
| `Wethmar_2001.pdf` | Wethmar U et al., Interactions of ligands at angiotensin…, Japanese journal of pharmac… (2001) | pd | 5 | [10.1254/jjp.85.167](https://doi.org/10.1254/jjp.85.167) | [11286399](https://www.ncbi.nlm.nih.gov/pubmed/11286399) | metadata signals extractable PD data (IC50) |
| `De_2003.pdf` | De Salvatore G et al., Effects of in vivo treatment with inter…, Autonomic & autacoid pharma… (2003) | pd | 4 | [10.1046/j.1474-8673.2003.00286.x](https://doi.org/10.1046/j.1474-8673.2003.00286.x) | [14511072](https://www.ncbi.nlm.nih.gov/pubmed/14511072) | metadata signals extractable PD data (Emax) |
| `Dehpour_1994.pdf` | Dehpour AR et al., Effects of atropine, pirenzepine, cloni…, General pharmacology (1994) | pd | 4 | [10.1016/0306-3623(94)90102-3](https://doi.org/10.1016/0306-3623(94)90102-3) | [7835643](https://www.ncbi.nlm.nih.gov/pubmed/7835643) | metadata signals extractable PD data (IC50) |
| `Ding_2023.pdf` | Ding N et al., The enhancing effect of 5-HT on phasic…, European journal of pharmac… (2023) | pd | 4 | [10.1016/j.ejphar.2023.175715](https://doi.org/10.1016/j.ejphar.2023.175715) | [37059373](https://www.ncbi.nlm.nih.gov/pubmed/37059373) | metadata signals extractable PD data (Emax) |
| `Kitazawa_1998.pdf` | Kitazawa T et al., Involvement of 5-hydroxytryptamine7 rec…, British journal of pharmaco… (1998) | pd | 4 | [10.1038/sj.bjp.0701583](https://doi.org/10.1038/sj.bjp.0701583) | [9489604](https://www.ncbi.nlm.nih.gov/pubmed/9489604) | metadata signals extractable PD data (EC50) |
| `Kohjitani_2005.pdf` | Kohjitani A et al., Peripheral N-methyl-D-aspartate recepto…, Anesthesia and analgesia (2005) | pd | 4 | [10.1213/01.ANE.0000184137.37687.B7](https://doi.org/10.1213/01.ANE.0000184137.37687.B7) | [16301241](https://www.ncbi.nlm.nih.gov/pubmed/16301241) | metadata signals extractable PD data (EC50) |
| `Lefebvre_1992.pdf` | Lefebvre RA et al., Relaxant effects of BRL 38227 and pinac…, European journal of pharmac… (1992) | pd | 4 | [10.1016/0014-2999(92)90087-k](https://doi.org/10.1016/0014-2999(92)90087-k) | [1582448](https://www.ncbi.nlm.nih.gov/pubmed/1582448) | metadata signals extractable PD data (Concentration-effect) |
| `Maggi_1994.pdf` | Maggi CA et al., Tachykinin NK3 receptor mediates NANC h…, Regulatory peptides (1994) | pd | 4 | [10.1016/0167-0115(94)90174-0](https://doi.org/10.1016/0167-0115(94)90174-0) | [7531357](https://www.ncbi.nlm.nih.gov/pubmed/7531357) | metadata signals extractable PD data (EC50) |
| `Menozzi_2018.pdf` | Menozzi A et al., Effects of selective α2 -adrenergic rec…, Journal of veterinary pharm… (2018) | pd | 4 | [10.1111/jvp.12470](https://doi.org/10.1111/jvp.12470) | [29164631](https://www.ncbi.nlm.nih.gov/pubmed/29164631) | metadata signals extractable PD data (Emax) |
| `Morris_1991.pdf` | Morris JL, Roles of neuropeptide Y and noradrenali…, Regulatory peptides (1991) | pd | 4 | [10.1016/0167-0115(91)90023-a](https://doi.org/10.1016/0167-0115(91)90023-a) | [1678196](https://www.ncbi.nlm.nih.gov/pubmed/1678196) | metadata signals extractable PD data (EC50) |
| `Wang_1993.pdf` | Wang YX et al., Functional integrity of the central and…, The Journal of pharmacology… (1993) | pd | 4 | not captured | [7682612](https://www.ncbi.nlm.nih.gov/pubmed/7682612) | metadata signals extractable PD data (Emax) |
| `da_2016.pdf` | da Silva MT et al., α-Terpineol Induces Gastric Retention o…, Planta medica (2016) | pd | 4 | [10.1055/s-0042-104657](https://doi.org/10.1055/s-0042-104657) | [27124242](https://www.ncbi.nlm.nih.gov/pubmed/27124242) | metadata signals extractable PD data (concentration-effect) |

<sub>queue written 2026-09-30T06:20:51.044863+00:00</sub>

## Screened and excluded

| domain | paper | verdict | relevance | extractability | reason |
|---|---|---|---|---|---|
| popPK | ARNOLD_1963 | irrelevant | 0 | 0 | no_text gate: only 112 chars of text extracted (&lt; 400) |
| popPK | Akata_1995 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of volatile anesthetics on mesenteric arteries, using guanethidine only as a non-specific blocker of nerve terminals, and reports no pharmacokinetic parameters for guanethidine. |
| PD | Akata_1995 | not_relevant | 0 | 0 | The paper studies the pharmacodynamics of volatile anesthetics (halothane, isoflurane, enflurane), not guanethidine, which is used only as a background agent to block nerve terminals. |
| popPK | Boerman_2016 | irrelevant | 0 | 0 | The study is a vascular physiology investigation in mice where guanethidine is used solely as a tool to inhibit sympathetic neurotransmission, not as the subject of pharmacokinetic analysis. |
| PD | Boerman_2016 | not_relevant | 0 | 0 | The paper uses guanethidine solely as a pharmacological tool to block sympathetic neurotransmission in an isolated organ bath experiment; it does not report a pharmacodynamic exposure-response or dose-response relationship for guanethidine itself. |
| popPK | Cession-Fossion_1965 | irrelevant | 0 | 0 | no_text gate: only 88 chars of text extracted (&lt; 400) |
| popPK | Chang_2018 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of bladder physiology where guanethidine is used only as a pharmacological tool to block adrenergic nerves, not as a subject for pharmacokinetic analysis. |
| PD | Chang_2018 | not_relevant | 2 | 1 | The paper uses guanethidine as a qualitative pharmacological tool to block adrenergic nerves in an in vitro study of phenylephrine-induced bladder relaxation; it does not report a dose-response curve or numeric PD parameters for guanethidine itself. |
| popPK | Consigny_2014 | irrelevant | 0 | 0 | The study uses guanethidine as a chemical agent for renal denervation in a rat model and reports neurochemical outcomes (NE depletion), not pharmacokinetic parameters. |
| PD | Consigny_2014 | not_relevant | 1 | 0 | The paper mentions guanethidine as a validated neurotoxic agent for renal denervation but does not report any dose-response or concentration-effect data for it; the only dose-response curve provided is for paclitaxel. |
| popPK | De_2003 | irrelevant | 0 | 0 | no_text gate: only 100 chars of text extracted (&lt; 400) |
| PD | De_2003 | not_relevant | 0 | 0 | The paper investigates the effects of interleukins 1beta and 6 on vascular reactivity and does not mention guanethidine or report any exposure-response or dose-response data for it. |
| popPK | Dehpour_1994 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of gastric fundus contractions where guanethidine is used only as a tool compound to block adrenergic transmission, not as the subject of a pharmacokinetic analysis. |
| PD | Dehpour_1994 | not_relevant | 0 | 0 | The paper reports IC50 values for atropine, pirenzepine, clonidine, morphine, and yohimbine, but guanethidine is only used as a fixed concentration (5 x 10^-6 M) to block adrenergic transmission; no dose-response curve or PD parameters are reported for guanethidine. |
| popPK | Dehpour_2002 | irrelevant | 0 | 0 | The study is a mechanistic pharmacology investigation of NANC relaxation in rat muscles where guanethidine is used only as a blocking agent, not as the subject of pharmacokinetic analysis. |
| PD | Dehpour_2002 | not_relevant | 0 | 0 | The paper uses guanethidine as a pharmacological tool to block adrenergic transmission, but does not report a dose-response or exposure-response relationship for guanethidine itself. |
| popPK | Dick_1997 | irrelevant | 0 | 0 | Guanethidine is used only as a pharmacological tool to block adrenergic transmission in an in-vitro study of NOS inhibitors, with no pharmacokinetic parameters reported. |
| PD | Dick_1997 | not_relevant | 0 | 0 | The paper investigates NOS inhibitors in pig gastric fundus; guanethidine is used only as a pharmacological tool to block adrenergic tone, not as the subject of a PD or exposure-response analysis. |
| popPK | Ding_2023 | irrelevant | 0 | 0 | no_text gate: only 126 chars of text extracted (&lt; 400) |
| PD | Ding_2023 | not_relevant | 0 | 0 | The paper investigates the pharmacology of 5-HT on human ureter and does not mention guanethidine or report any exposure-response or dose-response data for it. |
| popPK | Ewert_2006 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of Angiotensin II, where guanethidine is used only as a non-specific control agent to rule out adrenergic involvement, not as the subject of PK analysis. |
| PD | Ewert_2006 | not_relevant | 0 | 0 | The paper investigates the pharmacodynamics of Angiotensin II, not guanethidine; guanethidine is only mentioned as a negative control that did not affect the response. |
| popPK | Faghir-Ghanesefat_2017 | irrelevant | 0 | 0 | The study is a mechanistic pharmacology investigation of nicotinic receptors in rat tissue where guanethidine is used only as a non-specific adrenergic blocker, not as the subject of a pharmacokinetic analysis. |
| PD | Faghir-Ghanesefat_2017 | not_relevant | 0 | 0 | The paper investigates the role of α7-nAChR in rat corpus cavernosum using guanethidine only as a fixed-concentration blocker to isolate NANC responses, and does not report any exposure-response or dose-response relationship for guanethidine itself. |
| PGx | Fischer_1990 | not_relevant | 0 | 0 | The paper investigates the metabolism of fluperlapine, not guanethidine, and does not report pharmacogenomic effects on guanethidine PK/PD. |
| popPK | Gandía_1991 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of calcium channel blockade in chromaffin cells, not a pharmacokinetic study, and reports no disposition parameters for guanethidine. |
| popPK | Giuliani_1995 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of NK3 receptors in guinea-pig colon where guanethidine is used only as a non-specific adrenergic blocker, not as the subject drug for PK analysis. |
| PD | Giuliani_1995 | not_relevant | 0 | 0 | The paper studies the pharmacology of SR 142801 and senktide in isolated guinea-pig colon; guanethidine is used only as a non-specific pharmacological tool (adrenergic blocker) and no PD relationship or parameters for guanethidine are reported. |
| popPK | Grisk_2005 | irrelevant | 0 | 0 | The study uses guanethidine as a tool for neonatal sympathectomy to investigate renal artery function, not to characterize its pharmacokinetic parameters. |
| PD | Grisk_2005 | not_relevant | 0 | 0 | The paper uses guanethidine as a tool for neonatal sympathectomy and reports pharmacological responses to other agonists (NE, vasopressin, ET-1), but does not report a pharmacodynamic or exposure-response relationship for guanethidine itself. |
| popPK | Guettler_2008 | irrelevant | 0 | 0 | The study investigates the neuropharmacological mechanism of nitroglycerin tolerance using guanethidine as a tool compound, and does not report any pharmacokinetic parameters for guanethidine. |
| PD | Guettler_2008 | not_relevant | 1 | 0 | The paper investigates the mechanism of nitroglycerin tolerance using guanethidine as a pharmacological tool (microinjection) rather than analyzing the pharmacodynamic exposure-response relationship of guanethidine itself. |
| popPK | He_2025 | irrelevant | 0 | 0 | The paper is a computational drug repositioning study for COVID-19, diabetes, and Alzheimer's, and does not report pharmacokinetic parameters for guanethidine. |
| PD | He_2025 | not_relevant | 0 | 0 | The paper describes a computational framework for drug repositioning using transcriptomic data and does not report any pharmacodynamic or exposure-response analysis for guanethidine. |
| popPK | Jiang_1996 | irrelevant | 0 | 0 | The study is a mechanistic investigation of aortic sensitivity to nifedipine in hypertensive rats, where guanethidine is used only as an antihypertensive treatment agent, and no pharmacokinetic parameters for guanethidine are reported. |
| PD | Jiang_1996 | not_relevant | 0 | 0 | The paper investigates the pharmacodynamics of nifedipine on aortic rings, not guanethidine; guanethidine is only mentioned as a co-treatment for blood pressure control. |
| popPK | KIRKENDALL_1962 | irrelevant | 0 | 0 | no_text gate: only 75 chars of text extracted (&lt; 400) |
| PD | KIRKENDALL_1962 | not_relevant | 1 | 0 | The text is a title of a review article and does not contain the full text or specific numeric PD parameters for guanethidine. |
| popPK | Kamata_1988 | irrelevant | 0 | 0 | The study is a mechanistic pharmacology investigation of VIP and non-adrenergic non-cholinergic neurons in rat stomach, using guanethidine only as a blocking agent, and reports no pharmacokinetic parameters for guanethidine. |
| PD | Kamata_1988 | not_relevant | 0 | 0 | The paper reports PD parameters (IC50, EC50) for VIP, not guanethidine; guanethidine is used only as a pharmacological blocker to isolate non-adrenergic/non-cholinergic pathways. |
| popPK | Kim_1995 | irrelevant | 0 | 0 | The study is a mechanistic pharmacology investigation of VIP-mediated relaxation in rabbit tissue, where guanethidine is used only as a non-specific adrenergic blocker, not as the subject drug for PK analysis. |
| PD | Kim_1995 | not_relevant | 0 | 0 | Guanethidine is used only as a pharmacological tool to block adrenergic transmission, and no exposure-response or dose-response relationship for guanethidine itself is reported. |
| popPK | Kitazawa_1998 | irrelevant | 0 | 0 | no_text gate: only 118 chars of text extracted (&lt; 400) |
| PD | Kitazawa_1998 | not_relevant | 0 | 0 | The paper investigates the pharmacology of 5-hydroxytryptamine (serotonin) on porcine myometrium and does not mention guanethidine or report any exposure-response relationship for it. |
| popPK | Kohjitani_2001 | irrelevant | 0 | 0 | Guanethidine is used only as a pharmacological tool to block adrenergic nerves in an in-vitro mechanistic study, with no pharmacokinetic parameters reported. |
| PD | Kohjitani_2001 | not_relevant | 0 | 0 | Guanethidine is used only as a fixed-concentration pharmacological blocker to isolate NANC responses; the paper reports PD parameters (EC50) for ketamine and midazolam, not for guanethidine. |
| popPK | Kohjitani_2005 | irrelevant | 0 | 0 | The study is a mechanistic pharmacology investigation in rabbit esophageal smooth muscle where guanethidine is used only as a non-selective adrenergic blocker to isolate NANC responses, with no pharmacokinetic parameters reported. |
| PD | Kohjitani_2005 | not_relevant | 0 | 0 | Guanethidine is used only as a pharmacological tool to block adrenergic transmission in an in vitro tissue bath experiment; the paper reports PD parameters for NMDA receptor modulators (MK801, NMDA), not for guanethidine. |
| PGx | Konstandi_2006 | not_relevant | 0 | 0 | The paper uses guanethidine as a tool to deplete peripheral catecholamines to study CYP1A2 regulation, rather than reporting a pharmacogenomic effect on guanethidine's own PK or PD parameters. |
| PGx | Konstandi_2008 | not_relevant | 0 | 0 | The paper investigates the role of catecholamines in stress-induced CYP1A2 regulation using guanethidine as a pharmacological tool to deplete peripheral catecholamines, rather than reporting a pharmacogenomic effect of a gene variant on guanethidine's PK or PD. |
| popPK | Korolkiewicz_1997 | irrelevant | 0 | 0 | The study is a pharmacological investigation of galanin effects in rat gastric fundus where guanethidine is used only as a non-specific antagonist, with no pharmacokinetic parameters reported. |
| PD | Korolkiewicz_1997 | not_relevant | 0 | 0 | The paper studies galanin analogs; guanethidine is used only as a non-specific antagonist to rule out adrenergic involvement, with no dose-response or PD parameters reported for it. |
| popPK | LECOMTE_1964 | irrelevant | 0 | 0 | no_text gate: only 65 chars of text extracted (&lt; 400) |
| PD | LECOMTE_1964 | not_relevant | 0 | 0 | The paper discusses cystamine, not guanethidine, and does not report any exposure-response or dose-response relationship for the target drug. |
| popPK | Lefebvre_1992 | irrelevant | 0 | 0 | no_text gate: only 69 chars of text extracted (&lt; 400) |
| PD | Lefebvre_1992 | not_relevant | 0 | 0 | The paper investigates the relaxant effects of BRL 38227 and pinacidil, not guanethidine. |
| popPK | Maggi_1994 | irrelevant | 0 | 0 | The study is a pharmacological investigation of tachykinin receptors in guinea-pig colon, using guanethidine only as a non-specific adrenergic blocker, and reports no pharmacokinetic parameters. |
| PD | Maggi_1994 | not_relevant | 0 | 0 | The paper reports pharmacological data for tachykinins (senktide, neurokinin B), not guanethidine, which is used only as a background blocker. |
| popPK | Markowitz_1995 | irrelevant | 0 | 0 | The paper is a review of drug interactions and does not report original quantitative pharmacokinetic parameters for guanethidine. |
| PD | Markowitz_1995 | not_relevant | 1 | 0 | The paper is a qualitative review of drug interactions and does not report any numeric pharmacodynamic parameters or concentration-effect curves for guanethidine. |
| popPK | Martins_2006 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of CCK effects on rat duodenum where guanethidine is used only as a non-specific blocker, not as the subject drug for PK analysis. |
| PD | Martins_2006 | not_relevant | 0 | 0 | Guanethidine is used only as a pharmacological tool to block adrenergic transmission, and no exposure-response or dose-response relationship for guanethidine itself is reported. |
| popPK | Martínez_1994 | irrelevant | 0 | 0 | The study is a pharmacological investigation of vascular contraction where guanethidine is used only as a tool compound to block nerve stimulation, not as the subject of pharmacokinetic analysis. |
| PD | Martínez_1994 | not_relevant | 0 | 0 | The paper studies the pharmacology of the human deferential artery using noradrenaline and electrical stimulation; guanethidine is used only as a tool to block nerve-mediated contractions, and no exposure-response or dose-response relationship for guanethidine is reported. |
| popPK | Medina_2000 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of sildenafil on penile vessels where guanethidine is used only as a tool to block norepinephrine release, not as the subject of pharmacokinetic analysis. |
| PD | Medina_2000 | not_relevant | 0 | 0 | The paper investigates the pharmacodynamics of sildenafil, not guanethidine; guanethidine is used only as a tool compound to block norepinephrine release. |
| popPK | Meini_1996 | irrelevant | 0 | 0 | The study is a pharmacological assay for bradykinin receptors where guanethidine is used only as a non-specific blocker, not as the subject drug for PK analysis. |
| PD | Meini_1996 | not_relevant | 0 | 0 | The paper uses guanethidine as a non-specific blocker in a bradykinin receptor assay and does not report any pharmacodynamic or exposure-response relationship for guanethidine itself. |
| popPK | Menozzi_2018 | irrelevant | 0 | 0 | no_text gate: only 127 chars of text extracted (&lt; 400) |
| PD | Menozzi_2018 | not_relevant | 0 | 0 | The paper studies α2-adrenergic agonists in horse bronchi and does not mention guanethidine or report any exposure-response or dose-response data for it. |
| popPK | Middeke_2008 | irrelevant | 0 | 0 | The paper is a clinical review on dosing strategies for hypertension and mentions guanethidine only as a class of drug for withdrawal considerations, without reporting any pharmacokinetic parameters. |
| PD | Middeke_2008 | not_relevant | 1 | 0 | The text is a general review of dosing strategies and withdrawal phenomena; it mentions guanethidine only as an example of a drug requiring caution during withdrawal and provides no numeric PD parameters or concentration-effect data. |
| popPK | Minocha_1991 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of erythromycin's effects on guinea pig intestine, where guanethidine is used only as a tool compound to block adrenergic neurons, not as the subject of pharmacokinetic analysis. |
| PD | Minocha_1991 | not_relevant | 0 | 0 | The paper studies the pharmacodynamics of erythromycin, not guanethidine; guanethidine is only used as a control agent. |
| popPK | Morris_1991 | irrelevant | 0 | 0 | no_text gate: only 125 chars of text extracted (&lt; 400) |
| PD | Morris_1991 | not_relevant | 0 | 0 | The paper focuses on the roles of neuropeptide Y and noradrenaline in guinea-pig vasculature and does not mention guanethidine or report any exposure-response or dose-response data for it. |
| popPK | Nangle_2006 | irrelevant | 0 | 0 | The study is an in-vitro mechanistic investigation of neural regulation in mouse corpus cavernosum where guanethidine is used only as a pharmacological tool to block adrenergic transmission, not as the subject of a pharmacokinetic analysis. |
| popPK | Pagán_2009 | irrelevant | 0 | 0 | The study is a mechanistic pharmacological investigation of vascular smooth muscle contraction in pig radial arteries, using guanethidine only as a tool compound to block noradrenergic transmission, and reports no pharmacokinetic parameters. |
| PD | Pagán_2009 | not_relevant | 1 | 0 | The paper reports qualitative inhibition of neurogenic vasoconstriction by guanethidine in an organ bath study but does not provide numeric concentration-effect parameters or a quantitative PD model for guanethidine. |
| popPK | Pencheva_1993 | irrelevant | 0 | 0 | The study is a pharmacological investigation of GABA receptors in cat ileum where guanethidine is used only as a negative control agent, with no pharmacokinetic parameters reported. |
| PD | Pencheva_1993 | not_relevant | 0 | 0 | The paper studies GABA and GABA-A receptors; guanethidine is only mentioned as a negative control that had no effect, with no PD parameters reported for it. |
| popPK | Postorino_1993 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of neurotransmission where guanethidine is used only as a blocking agent, not as the subject of pharmacokinetic analysis. |
| PD | Postorino_1993 | not_relevant | 0 | 0 | The paper uses guanethidine only as a pharmacological tool to block adrenergic transmission and does not report any exposure-response or dose-response relationship for guanethidine itself. |
| popPK | REUSE_1960 | irrelevant | 0 | 0 | no_text gate: only 44 chars of text extracted (&lt; 400) |
| PD | REUSE_1960 | not_relevant | 0 | 0 | The provided text contains only the title and no body content, so no numeric PD parameters or exposure-response relationships can be extracted. |
| popPK | Radomirov_1992 | irrelevant | 0 | 0 | The study is a pharmacological investigation of endothelin-1 effects on rat vas deferens where guanethidine is used only as a tool drug to block sympathetic innervation, not as the subject of a pharmacokinetic analysis. |
| PD | Radomirov_1992 | not_relevant | 0 | 0 | The paper studies the effect of endothelin-1 on rat vas deferens; guanethidine is used only as a tool to block sympathetic innervation, and no exposure-response or dose-response relationship for guanethidine itself is reported. |
| popPK | Ralevic_1994 | irrelevant | 0 | 0 | The study is a mechanistic pharmacology paper on neuropeptide Y in rat mesenteric arteries, where guanethidine is used only as a tool to block sympathetic transmission, and no pharmacokinetic parameters are reported. |
| PD | Ralevic_1994 | not_relevant | 0 | 0 | The paper focuses on the pharmacology of neuropeptide Y and its antagonist alpha-trinositol; guanethidine is used only as a tool to block sympathetic transmission and no PD parameters for guanethidine are reported. |
| popPK | Ralevic_1996 | irrelevant | 0 | 0 | The study is a mechanistic pharmacology investigation of vitamin E deficiency in rat mesenteric arteries where guanethidine is used only as a tool compound to block sympathetic transmission, not as the subject of a pharmacokinetic analysis. |
| PD | Ralevic_1996 | not_relevant | 0 | 0 | The paper uses guanethidine as a fixed-concentration tool compound to block sympathetic tone, but does not report a dose-response or exposure-response relationship for guanethidine itself. |
| popPK | Ralevic_1996_2 | irrelevant | 0 | 0 | The study is a pharmacodynamic investigation of vasoconstrictor responses in rat mesenteric arteries, using guanethidine only as a tool for sympathectomy, and reports no pharmacokinetic parameters. |
| popPK | Ren_1994 | irrelevant | 0 | 0 | The study is a pharmacological investigation of vascular responses in isolated canine arteries where guanethidine is used only as a tool to inhibit nerve stimulation, not as a subject for pharmacokinetic analysis. |
| PD | Ren_1994 | not_relevant | 1 | 0 | The paper mentions guanethidine only qualitatively as an inhibitor of nerve-stimulated vasoconstriction, without providing any numeric dose-response data, concentration-effect curves, or PD parameters for guanethidine itself. |
| popPK | Sasaki_2007 | irrelevant | 0 | 0 | The study is a mechanistic organ culture experiment investigating testicular descent, using guanethidine only as a pharmacological antagonist without reporting any pharmacokinetic parameters. |
| PD | Sasaki_2007 | not_relevant | 1 | 0 | The paper reports a qualitative observation that guanethidine had no effect on contractility compared to baseline, but provides no numeric concentration-effect data, dose-response curve, or PD parameters for guanethidine. |
| popPK | Segarra_1999 | irrelevant | 0 | 0 | The study is a mechanistic investigation of adrenergic contraction in isolated dog pulmonary arteries where guanethidine is used only as a pharmacological tool to block nerve stimulation, not as the subject of a pharmacokinetic analysis. |
| PD | Segarra_1999 | not_relevant | 0 | 0 | Guanethidine is used only as a tool compound to block neurogenic contractions; no exposure-response or dose-response relationship for guanethidine itself is reported. |
| popPK | Silva_2005 | irrelevant | 0 | 0 | The study is an in-vitro pharmacodynamic investigation of phentolamine in human corpus cavernosum, where guanethidine is used only as a background agent to block adrenergic influences, and no pharmacokinetic parameters are reported. |
| popPK | Simionescu_1979 | irrelevant | 0 | 0 | no_text gate: only 128 chars of text extracted (&lt; 400) |
| PD | Simionescu_1979 | not_relevant | 1 | 0 | The text is a title/abstract snippet describing a qualitative review of nonspecific pharmacodynamics without providing any numeric PD parameters or concentration-effect data. |
| popPK | Spencer_1998 | irrelevant | 0 | 0 | The study is an in-vitro electrophysiology experiment using guanethidine as a pharmacological tool to block sympathetic responses, not a pharmacokinetic study reporting disposition parameters. |
| popPK | Tabrizchi_1992 | irrelevant | 0 | 0 | The study investigates the hemodynamic effects of angiotensin II in rats using guanethidine as a pharmacological tool to block sympathetic neurons, rather than reporting pharmacokinetic parameters for guanethidine. |
| PD | Tabrizchi_1992 | not_relevant | 0 | 0 | The paper investigates the dose-response relationship of angiotensin II, not guanethidine; guanethidine is used only as a pretreatment to block sympathetic effects. |
| popPK | Van_2001 | irrelevant | 0 | 0 | The study investigates the contractile effects of motilin and erythromycin on human colon smooth muscle, using guanethidine only as a non-interfering control agent, and reports no pharmacokinetic parameters. |
| PD | Van_2001 | not_relevant | 0 | 0 | The paper investigates the pharmacodynamics of motilin and erythromycin, mentioning guanethidine only as a negative control that did not interfere with the effects, without reporting any dose-response or exposure-response data for guanethidine itself. |
| popPK | Vassilev_1992 | irrelevant | 0 | 0 | The study is a pharmacological investigation of prostaglandin effects in rat rectum where guanethidine is used only as a non-pharmacokinetic pharmacological tool, with no PK parameters reported. |
| PD | Vassilev_1992 | not_relevant | 0 | 0 | The paper investigates the contractile effects of prostaglandin E2 and its antagonists; guanethidine is used only as a pharmacological tool to block neural effects, and no exposure-response or dose-response relationship for guanethidine itself is reported. |
| popPK | Venkova_2000 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of neuromuscular function where guanethidine is used as a blocking agent, not a pharmacokinetic study of the drug's disposition. |
| PD | Venkova_2000 | not_relevant | 0 | 0 | The paper uses guanethidine as a pharmacological tool to block adrenergic transmission in an in vitro neuromuscular study, not to characterize the pharmacodynamic exposure-response relationship of guanethidine itself. |
| popPK | Wang_1993 | irrelevant | 0 | 0 | no_text gate: only 188 chars of text extracted (&lt; 400) |
| PD | Wang_1993 | not_relevant | 0 | 0 | The paper investigates the effects of diphenyleneiodonium, not guanethidine, and does not report any pharmacodynamic parameters for guanethidine. |
| popPK | Wethmar_2001 | irrelevant | 0 | 0 | The study is an in-vitro receptor binding/displacement experiment and does not report any pharmacokinetic disposition parameters for guanethidine. |
| PD | Wethmar_2001 | not_relevant | 0 | 0 | The paper discusses ligand interactions at angiotensin II and imidazoline receptors but does not report any pharmacodynamic or exposure-response data for guanethidine. |
| popPK | Yamamoto_1987 | irrelevant | 0 | 0 | The study focuses on coronary artery spasm pathogenesis in swine, using guanethidine only as a nerve transmitter blocker to test mechanism, with no pharmacokinetic parameters reported. |
| PD | Yamamoto_1987 | not_relevant | 0 | 0 | The paper studies histamine-induced coronary spasm; guanethidine is used only as a blocker to show it does not influence the histamine dose-response, and no PD parameters for guanethidine itself are reported. |
| popPK | Yu_1992 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of furosemide on equine trachealis muscle, where guanethidine is used only as a pretreatment agent to block sympathetic transmission, not as the subject of pharmacokinetic analysis. |
| PD | Yu_1992 | not_relevant | 0 | 0 | The paper investigates the effect of furosemide on equine trachealis, using guanethidine only as a pretreatment to block adrenergic transmission, and does not report any pharmacodynamic or exposure-response relationship for guanethidine itself. |
| popPK | da_2016 | irrelevant | 0 | 0 | The study focuses on the pharmacodynamics of α-terpineol on gastric emptying, using guanethidine only as a mechanistic probe without reporting any pharmacokinetic parameters for it. |
| PD | da_2016 | not_relevant | 0 | 0 | The paper focuses on the pharmacodynamics of alpha-terpineol; guanethidine is only mentioned as a negative control agent that did not interfere with the effect, with no exposure-response or dose-response analysis provided for it. |
| popPK | van_2000 | irrelevant | 0 | 0 | The study is an in-vitro pharmacological investigation of mibefradil where guanethidine is used only as a tool compound to block sympathetic neurotransmitter release, with no pharmacokinetic parameters reported. |
| PD | van_2000 | not_relevant | 0 | 0 | The paper studies mibefradil and verapamil; guanethidine is only used as a tool compound to block EFS, not as the subject of a PD or exposure-response analysis. |

---
<sub>Generated by `docs.py` (scholarv2)</sub>
